Thursday, November 03, 2011 2:38:06 PM
Don,t forget they have applied for orphan drug status for burn indication and they are in discussion with FDA regarding trial design for ance scar, clarity on those topics will raise the possibility of partnership.
China JV will start paying off in 2012 and if that gives good revenue that will be big plus, as FCSC is only giving intellectual property to them other expenses will be incurred through the china partner.
other potential mid term indication:
vocal cord scarring,
and periondontal disease(HUGE, if successful)
long term:
ACl ligament repair
cell therapy(UCLA COLLOBORATION)
The only thing and most important thing missing is good partnership(Financing) , everything else will unfold very well once that happens.
I might be totally wrong , just my opinion.
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM